pharmaceutical investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
pharmaceutical investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
Alvopetro Announces Q3 2025 Financial Results and an Operational Update Including Record October Sales
Altech Batteries Ltd Service Data Confirms Exceptionally Low Failure Rate for Sodium-Nickel-Chloride Batteries
Allied Critical Metals Expands Santa Helena Breccia with 6.0 Metres of 1.02% WO3 Intercept at Borralha
